Table 4.

Literature test set predictions from the quantitative pharmacophore model and Bayesian model. Compounds are listed in decreasing order of fit value (FAST conformer method)

Drug	Ki or IC50 (μM)	Quantitative pharmacophore fit valuea	Predicted Ki (μM)a	Quantitative pharmacophore fit valueb	Predicted Ki (μM)b	Bayesian score	Maximal Tanimoto similarity to training set compound	Experimental system
Cetirizine28	27	4.24	133	5.34	10.8	0.175	0.60 (raloxifene)	Caki-1 (human proximal tubule cell line)
Emetine29	4.2	4.29	118	4.15	162	2.92	0.70 (verapamil)	Xenopus laevis oocytes
Acebutolol6	Not inhibitor	2.59	5860	2.46	7960	−11.3	0.79 (atenolol)	hOCTN2-Transfected MDCKII Cells
Cefoselis7	6400	0.134	0.134	3.48	754	−5.78	0.65 (acyclovir)	Hela with human OCTN2
Famotidine28	1920	0.0259	2.16E+06	0.376	963000	−6.35	0.56 (hydrochlorthiazide)	Caki-1
Zidovudine30	6	NM	NM	NM	NM	−7.49	0.63 (guanosine)	Mouse myoblastic C2C12 cells
Omeprazole31	14.6	NM	NM	NM	NM	−0.37	0.52 (vinblastine)	Rat kidney OCTN2 reconstituted in liposomes
Mildronate6	26	NM	NM	NM	NM	−0.967	0.50 (propantheline)	hOCTN2-Transfected MDCKII Cells
Spironolactone6	26	NM	NM	NM	NM	−0.589	0.39 (atropine)	hOCTN2-Transfected MDCKII Cells
Ciclotropium28	30	NM	NM	NM	NM	−2.93	0.72 (atropine)	Caki-1
Ipratropium4, 28	95	NM	NM	NM	NM	−9.62	0.89 (atropine)	HEK stable cell line with human OCTN2
Valproic acid28	139	NM	NM	NM	NM	−0.767	0.23 (atropine, lomefloxacin, verapamil and vinblastine)	Caki-1
Cephaloridine7, 28	230/248	NM	NM	NM	NM	−1.23	0.57 (bromocriptine)	Hela/ Caki-1 (human proximal tubule cell line)
Grepafloxacin32	300	NM	NM	NM	NM	−16.3	0.96 (lomefloxacin)	BeWo (human placental cell line)
Cimetidine28	336	NM	NM	NM	NM	−6.00	0.56 (pramipexole)	Caki-1
Tacrine33	500	NM	NM	NM	NM	−3.13	0.54 (desloratidine)	HEK stable cell line with rat OCTN2
(−)-N- butylscopolamine28	1007	NM	NM	NM	NM	−9.31	0.73 (atropine)	Caki-1
Cefepime7	1700	NM	NM	3.80	363	−5.42	0.63 (bromocriptine)	Hela with human OCTN2
Levofloxacin32	3000	NM	NM	NM	NM	−10.4	0.81 (lomefloxacin)	BeWo
Metformin28	4963	NM	NM	NM	NM	−4.03	0.32 (clozapine)	Caki-1
Captopril6	Not inhibitor	NM	NM	NM	NM	−4.32	0.53 (atropine)	hOCTN2-Transfected MDCKII Cells
Cisplatin34	Not inhibitor	NM	NM	NM	NM	−2.98	0.28 (sulfanilamide)	L6 stable cell line with rat OCTN2
Cefazolin35	6740	NM	NM	NM	NM	−3.88	0.57 (guanosine)	L6 cells overexpressing hOCTN2
Cefuroxime35	525	NM	NM	NM	NM	−5.25	0.57 (bromocriptine)	L6 cells overexpressing hOCTN2
Cephalexin35	3037	NM	NM	NM	NM	−6.35	0.53 (lomefloxacin)	L6 cells overexpressing hOCTN2
Digoxin6	Not inhibitor	NM	NM	NM	NM	−1.62	0.56 (vinblastine)	hOCTN2-Transfected MDCKII Cells
Diphenhydramine36	Not inhibitor	NM	NM	NM	NM	−0.0798	0.63 (propantheline)	Mouse enterocyte
Lidocaine36	Not inhibitor	NM	NM	NM	NM	−4.13	0.48 (atenolol)	Mouse enterocyte
Memantine6	Not inhibitor	NM	NM	NM	NM	−1.73	0.29 (pramipexole)	hOCTN2-Transfected MDCKII Cells
Metoprolol6	Not inhibitor	NM	NM	NM	NM	−10.9	0.76 (atenolol)	hOCTN2-Transfected MDCKII Cells
Probenecid36	Not inhibitor	NM	NM	NM	NM	−3.22	0.54 (sulfanilamide)	Mouse enterocyte
Oxaliplatin34	Not inhibitor	NM	NM	NM	NM	−2.34	0.50 (guanosine)	L6 stable cell line with rat OCTN2

^aFit values and predicted K_i values are derived from the pharmacophore using the FAST conformer method.

^bFit values and predicted K_i values are derived from the pharmacophore using the BEST conformer method.

NM denotes compound did not map to the pharmacophore.